Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects

Area of Science:

• Biochemistry and Pharmacology
• Toxicology and Diabetes Research

Background:

• Tungstate, an oxyanion with biological similarities to vanadate, has demonstrated antidiabetic effects in animal models.
• Concerns exist regarding the chronic administration of vanadium and tungsten compounds due to potential tissue accumulation and toxicity.
• Vanadium derivatives are associated with various toxic effects, including hematological, biochemical, nephrotoxic, immunotoxic, reproductive, developmental, and behavioral issues, as well as mitogenic activity.

Purpose of the Study:

• To review and compare the toxic effects of vanadium derivatives with those reported for tungsten in the context of potential human diabetes mellitus treatment.
• To highlight the scarcity of data on tungstate's toxicity, especially cellular toxicity, despite its emerging role as a potential oral antidiabetic agent.

Main Methods:

• Review of existing literature on the toxic effects of vanadium and tungsten compounds.
• Comparison of reported toxicological data for both elements.
• Identification of knowledge gaps concerning tungstate's toxicity in mammals.

Main Results:

• Vanadium compounds exhibit a range of toxic effects, including hematological and biochemical alterations, organ toxicity, and genotoxicity.
• Early studies indicated tungstate is less toxic than vanadate when administered intravenously.
• Limited information exists on the cellular toxicity of tungstate, despite in vitro evidence of embryonic and fetal effects in mice.

Conclusions:

• While tungstate shows potential as an oral antidiabetic agent, its pharmacological use is limited by concerns over chronic toxicity.
• A comprehensive evaluation of tungstate's toxicity in mammals is essential given its recent interest in diabetes treatment.
• Further research is critically needed to fully understand and mitigate potential risks associated with tungstate therapy.